Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH®

IBA announced the first patient treatment in the C-FLASH-01 clinical trial, a groundbreaking feasibility study for ConformalFLASH® proton therapy conducted by Penn Medicine under FDA authorization. The trial evaluates fractioned proton therapy delivered at the Bragg peak for head and neck cancer patients requiring re-irradiation. IBA is actively supporting the clinical evaluation as trial sponsor, partnering with RaySearch Laboratories, 3D Systems, .decimal, and IBA Dosimetry to advance FLASH radiotherapy toward clinical practice.